Actively Recruiting
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Led by Sun Yat-sen University · Updated on 2025-11-17
69
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.
CONDITIONS
Official Title
Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of esophageal squamous cell carcinoma confirmed by tissue tests
- Locally advanced, unresectable esophageal cancer based on imaging and staging (T2-4, N0-3, M0-1 with M1 limited to supraclavicular lymph node metastasis)
- Male or female aged between 18 and 80 years
- No previous chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy
- Expected life expectancy of at least 12 weeks
- ECOG performance status of 0 or 1
- Adequate organ and bone marrow function as defined by specific laboratory values
- Signed informed consent obtained prior to study procedures
You will not qualify if you...
- Participation in another clinical trial at the same time, except observational studies
- Prior use of any targeted therapy
- Major surgery within 4 weeks before entering the study (except vascular access procedures)
- Uncontrolled comorbidities such as active infections, symptomatic heart failure, uncontrolled hypertension, unstable angina, arrhythmias, active ulcers, intestinal problems, bleeding disorders, or psychiatric/social conditions affecting compliance
- Performance status score of 2 to 4
- Organ or bone marrow dysfunction below defined laboratory thresholds
- Any condition that may interfere with evaluating the safety or effectiveness of surufatinib
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
B
Bo Qiu
CONTACT
H
Hui Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here